Logo image
Infant Renal Replacement Therapy Using Carpediem™: A Multicenter Observational Cohort Study from the ICONIIC Learning Network
Journal article   Open access   Peer reviewed

Infant Renal Replacement Therapy Using Carpediem™: A Multicenter Observational Cohort Study from the ICONIIC Learning Network

Cara L Slagle, Kim T Vuong, Kelli A Krallman, Lauren Casey, Katja M Gist, Jennifer G Jetton, Catherine Joseph, Kera Luckritz, Susan D Martin, Jolyn Morgan, …
The Journal of pediatrics, Vol.288, 114838
01/2026
DOI: 10.1016/j.jpeds.2025.114838
PMID: 41016463
url
https://doi.org/10.1016/j.jpeds.2025.114838View
Published (Version of record) Open Access

Abstract

To evaluate indications and outcomes of Carpediem™ as the first infant-specific continuous renal replacement therapy (CRRT) platform available for clinical use in the US. A multicenter, retrospective and prospective observational study was conducted through the "Improving CRRT Outcomes in Neonates and Infants through Interdisciplinary Collaboration (ICONIIC)" Learning Network. Data were collected from the first four US centers utilizing Carpediem™. A treatment course was defined as sequential CRRT procedures separated by ≤72 hours. Infant cohorts were categorized by CRRT indication: end-stage kidney disease (ESKD) (ie, CRRT as a bridge to PD) and non-ESKD (all other indications). Sixty-seven infants underwent 93 treatment courses using 1,538 filters and 112 vascular access catheters. Primary indication for CRRT was ESKD in 36 (54%) and acute kidney injury in 43%. Median age at first treatment was 18 (IQR: 6, 81) days, and dry weight 2.6 (IQR: 2.4, 3.1) kg for the ESKD cohort and 32 (IQR: 9, 90) days and 3.4 (IQR: 3.2, 4.5])kg for the non-ESKD cohort. Median treatment course duration was 12 (IQR: 3,24) days for ESKD compared with 4 [IQR: 1,13] days for non-ESKD infants. Survival to hospital discharge was 67% in ESKD and 60% in non-ESKD. In this US cohort study, CRRT survival in infants treated with Carpediem™ exceeds 60%. More than half of the treatment indications were for ESKD as a bridge to dialysis.
ICONIIC end stage kidney disease continuous kidney replacement therapy fluid overload Carpediem congenital kidney failure neonatal acute kidney injury infant pediatric

Details

Metrics

17 Record Views
Logo image